This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07668388 |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 300 participants |
| Design | Interventional, Randomized, Parallel, Double-blind, Placebo- and active-controlled |
| Conditions | Type 2 Diabetes Mellitus |
| Interventions | UBT251; UBT251 placebo; Semaglutide; Semaglutide placebo |
| Start | Jun 22, 2026 |
| Primary completion | Oct 4, 2027 |
| Study completion | Nov 15, 2027 |
| Results posted | Not yet |
| Registry last updated | Not stated |
Compounds on this site that cite this trial
What the registry says the trial is about
Novo Nordisk phase 2 dose-finding study in adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor. Participants receive UBT251, UBT251 placebo, semaglutide or semaglutide placebo by chance. Sites in nine countries.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| UBT251: change in HbA1c from baseline to 12 weeks on a given maintenance dose (weeks 16, 28 and 40) | Weeks 16, 28, 40 |
24 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 1, 2026. See the trial changes feed for what has changed recently.
More trials of UBT251
- UBT251 Injection Phase II Study in Type 2 Diabetes, With Semaglutide Comparator (Phase 2 NCT07163624)
- UNIGUIDE-1: UBT251 Phase 3 in Type 2 Diabetes on Diet and Exercise Alone (Phase 3 NCT07659574)
- UNIGUIDE-2: UBT251 Phase 3 Against Semaglutide in Type 2 Diabetes (Phase 3 NCT07653477)
- UBT251 Injection Phase Ⅲ Study (OSA-PAP) (Phase 3 NCT07806851)
- UBT251 Injection Phase Ⅲ Study (OSA-NPAP) (Phase 3 NCT07767942)
- UBT251 Phase 3 in Overweight or Obesity (China) (Phase 3 NCT07648225)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
